BRIEF-Kyprolis (Carfilzomib) Extended Overall Survival In Patients With Relapsed Or Refractory Multiple Myeloma
December 11, 2017 at 16:09 PM EST
* KYPROLIS® (CARFILZOMIB) EXTENDED OVERALL SURVIVAL IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA IN PHASE 3 ASPIRE TRIAL